Point72 Asset Management
PTGX icon

Point72 Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Point72 Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-135,000
Closed -$1.07M – 1677
2022
Q2 		$1.07M Buy
+135,000
New +$1.63M ﹤0.01% 1058

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management's PTGX Position: Q4 2024 in Review

Point72 Asset Management sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 214,872 shares — an estimated $9.67M sold.

Point72 Asset Management first reported a position in PTGX in Q4 2017 and held it in 16 quarters. The position peaked at $82.8M in Q4 2021. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Point72 Asset Management reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Asset Management sold 214,872 Protagonist Therapeutics shares in Q4 2024, an estimated $9.67M.
  • Point72 Asset Management first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 16 quarters.
  • Point72 Asset Management's Protagonist Therapeutics position peaked at $82.8M in Q4 2021.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Point72 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.